Skip to main content

Table 1 Mean (SD) WPAI:M Subscores, by Treatment and Week

From: Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study

 

Baseline

Week 4

Week 8

Week 12

Week 16

Week 20

Week 24

Absenteeism

 Eptinezumab 100 mg

11.4 (19.4)

4.7 (12.4)

4.7 (11.2)

5.8 (12.3)

5.7 (13.3)

6.4 (16.1)

6.0 (15.5)

 Eptinezumab 300 mg

12.0 (19.3)

3.2 (8.2)

6.3 (17.4)

6.0 (16.9)

4.4 (12.9)

6.1 (15.0)

5.2 (12.6)

 Placebo

12.9 (20.1)

9.5 (18.4)

10.0 (20.3)

11.3 (21.2)

9.0 (17.2)

12.2 (22.4)

9.8 (18.7)

Presenteeism

 Eptinezumab 100 mg

50.8 (25.6)

26.7 (26.6)

26.5 (26.7)

32.3 (28.1)

30.4 (28.2)

27.3 (26.2)

28.2 (25.1)

 Eptinezumab 300 mg

53.4 (24.0)

26.3 (25.4)

28.0 (26.4)

26.1 (24.5)

25.3 (25.3)

26.7 (27.1)

30.4 (27.1)

 Placebo

51.7 (24.2)

40.0 (25.6)

41.7 (27.5)

39.9 (26.2)

42.8 (27.4)

40.2 (29.3)

41.5 (28.3)

Work Productivity Loss

 Eptinezumab 100 mg

53.7 (26.2)

28.8 (28.0)

28.8 (28.4)

34.6 (29.6)

32.5 (29.9)

29.5 (27.9)

30.5 (27.0)

 Eptinezumab 300 mg

57.0 (24.1)

27.7 (26.5)

30.2 (27.9)

28.1 (26.0)

26.9 (26.5)

29.1 (28.9)

32.5 (28.6)

 Placebo

55.6 (24.7)

43.5 (27.0)

44.6 (28.9)

43.3 (27.7)

45.9 (28.8)

43.5 (31.0)

45.0 (29.4)

Activity Impairment

 Eptinezumab 100 mg

58.5 (23.5)

34.2 (28.4)

32.7 (28.6)

34.9 (27.1)

31.4 (27.5)

31.5 (27.2)

31.0 (25.9)

 Eptinezumab 300 mg

59.1 (23.4)

32.6 (28.3)

31.6 (28.2)

31.9 (26.7)

29.4 (27.0)

30.5 (28.2)

33.1 (27.0)

 Placebo

58.7 (23.5)

45.5 (25.4)

44.6 (26.9)

44.7 (26.9)

45.5 (26.3)

43.4 (29.0)

45.2 (27.0)

  1. Subscores represent raw mean percentage of time. SD standard deviation, WPAI:M Work Productivity and Activity Impairment: Migraine